Replies to post #42 on MyMD Pharmaceuticals Inc (MYMD)

[leifsmith]

MyMD-1: No global immunosuppression - significant

From the abstract quoted by BioFan1:

MYMD-1 improved the course of EAE and suppressed activation of effector T cells without causing global immunosuppression or toxicity. These results suggest that MYMD-1 may be of interest for evaluating for the treatment of autoimmune diseases.

How many anti-inflammation drugs can make such a claim? My guess is that this benign result will be found in MYMD-1 treatment of all inflammatory involving diseases.